Cargando…
Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer
BACKGROUND: Murine studies suggest that myeloid cells such as vascular leukocytes (VLC) and Tie2(+ )monocytes play a critical role in tumor angiogenesis and vasculogenesis. Myeloid cells are a primary cause of resistance to anti-VEGF therapy. The elimination of these cells from the tumor microenviro...
Autores principales: | Pulaski, Heather L, Spahlinger, Gregory, Silva, Ines A, McLean, Karen, Kueck, Angela S, Reynolds, R Kevin, Coukos, George, Conejo-Garcia, Jose R, Buckanovich, Ronald J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704183/ https://www.ncbi.nlm.nih.gov/pubmed/19545375 http://dx.doi.org/10.1186/1479-5876-7-49 |
Ejemplares similares
-
BMPs morph into new roles in ovarian cancer
por: McLean, Karen, et al.
Publicado: (2013) -
The role of dendritic cell precursors in tumour vasculogenesis
por: Coukos, G, et al.
Publicado: (2005) -
Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling
por: Raghavan, Shreya, et al.
Publicado: (2020) -
Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009) -
Antiangiogenic therapies in ovarian cancer
por: Reinthaller, Alexander
Publicado: (2016)